BRIEF-Arch Biopartners to manufacture drug AB569 with Catalent Inhalation

Wed Aug 10, 2016 8:15am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Aug 10 (Reuters) - Arch Biopartners Inc :

* Engaged Catalent Inhalation, a division of Catalent Pharma Solutions, to begin manufacturing process for drug ab569

* Catalent Inhalation to undertake initial stability and formulation studies, later manufacture a supply of ab569

* Engaged Catalent Inhalation in preparation for first human trials involving patients with antibiotic resistant lung infections Source text for Eikon: Further company coverage: